BattelleCRO, Inc. and Msource Medical Development Sign Joint Marketing agreement to Provide Support and Service For Pharmaceutical, Biotechnology and Medical Device Clients

Newton, Massachusetts, and Kraainem, Belgium - December 5, 2006 -

 

BattelleCRO, Inc. (BattelleCRO) a leading full-service Contract Research Organization with more than 10 years experience, announced today that it has signed a non-exclusive joint marketing agreement with MSOURCE Medical Development (MSOURCE). MSOURCE is a full-service Contract Research Organization, which provides Phase II-IV services for clinical trials conducted throughout Europe.

 

This collaboration allows for the seamless integration of both companies resources in responding to the global clinical trial demands of pharmaceutical, biotechnology and medical device clients. By being able to jointly market each other's capabilities within their respective countries, clients can gain the advantage of working with a multinational organization without having to absorb the additional overhead of paying for infrastructure when it is not being fully utilized.

"This agreement with MSOURCE is part of our overall international partner strategy. Extending our global reach into the European countries provides us not only with access to a large patient population but allows us to take full advantage of local medical, clinical and regulatory expertise," remarked Howard Golub, PhD, MD, President of BattelleCRO, Inc.

 

"Working closely with our international partners like MSOURCE provides a number of distinct advantages for our clients, specifically: access to patients around the globe and expert resources that understand the regulatory environment, the language and the local customs. Partnering allows us to place studies into the countries where it is most appropriate and not where we happen to have excess capacity," added Peter C. Powers, Vice President, Business Development of BattelleCRO, Inc.

 

"We are delighted to partner with BattelleCRO for the conduct of global clinical trials and registries," says Adriaan Hart de Ruyter, Chief Executive Officer of MSOURCE Medical Development. "MSOURCE's European strategy, including acquisitions and the buildup of resource capacity in every single European country, aligns well with BatelleCRO's strategy. Europe requires specialist knowledge of submission procedures, local patient populations and medical practices."

 

About BattelleCRO

 

BattelleCRO is a wholly owned subsidiary of Battelle that supports Phase I-IV clinical development programs for pharmaceutical, biotechnology, medical device, nutraceutical, government clients, and bio-defense efforts (including chemical and biomedical countermeasures). As a full service one-stop provider, BattelleCRO supports the client's overall market strategy from toxicology, through IND submissions, clinical trials, FDA approval, and post-marketing monitoring. For more information, visit www.BattelleCRO.com or contact Peter C. Powers at (617) 618-5103; e-mail: ppowers@battellecro.com.

 

About MSOURCE

 

MSOURCE is a full-service Contract Research Organization providing a range of clinical development services to the pharmaceutical, biotechnology, and medical device industries. MSOURCE has clinical operations covering a broad range of therapeutic areas across Europe and the US. MSOURCE complies with the stringent demands of the FDA and EMEA. MSOURCE's management team is committed to continuous quality improvement because only this dedication leads to reliable study results, excellent investigator relationships and client confidence. MSOURCE services are accredited with ISO 9001:2000. From our four offices in Belgium, the Netherlands, Germany, Poland and the UK and our Europe-wide network of study monitors and investigators, we are able to respond to client demands quickly and appropriately. With our never-ending commitment to quality we are able to keep on improving and expanding our services. For more information, visit www.msource-cro.com or contact Simon Crowe at +44 1442 450410; e-mail: scrowe@msource-cro.com.

 

About Battelle

 

Battelle is a global leader in science and technology. Headquartered in Columbus, Ohio, it develops and commercializes technology and manages laboratories for customers. Battelle, with the national labs that it manages or co-manages, oversees 20,000 staff members and conducts $3.4 billion in annual research and development. Battelle provides complete safety pharmacology, cardiovascular and respiratory physiology, pulmonary delivery, and other non-clinical safety assessment services to pharmaceutical and biotechnology clients. Battelle also provides analytical chemistry capabilities for pre-clinical and clinical drug development and expertise for analyzing and interpreting PK/TK data for such purposes as chemical safety evaluations, risk assessments, and/or IND applications. For more information, visit www.battelle.org or contact Michael Brooker at (614) 424-6372; e-mail: brookerm@battelle.org.